Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure
Key Clinical Message Philadelphia‐negative (Ph−) myeloproliferative neoplasms (MPN) do rarely transform to acute lymphoblastic leukemia (ALL). While causality is difficult to establish, a few cases of ALL arising after exposure to lenalidomide for registered indications (multiple myeloma, myelodysplastic syndrome with 5q deletion) have been described in the literature. Philadelphia‐negative (Ph−) myeloproliferative neoplasms (MPN) do rarely transform to acute lymphoblastic leukemia (ALL). While causality is difficult to establish, a few cases of ALL arising after exposure to lenalidomide for registered indications (multiple myeloma, myelodysplastic syndrome with 5q deletion) have been described in the literature.
Authors: Belay Y, Yirdaw K, Enawgaw B Abstract Tumor lysis syndrome is a metabolic complication that may follow the initiation of cancer therapy. It commonly occurs in hematological malignant patients particularly non-Hodgkin's lymphoma and acute leukemia due to chemotherapy or spontaneously. It is characterized by a biochemical abnormality such as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia and its clinical outcome is directly related to these biochemical abnormalities. Prevention and treatment of tumor lysis syndrome depend on immediate recognition of patients at risk. Therefore, identifying ...
Condition: Acute Myeloid Leukemia Interventions: Other: Usual Care; Other: Psychological intervention Sponsor: Massachusetts General Hospital Not yet recruiting
Conditions: Lymphoma; Solid Malignancy; Alzheimer Disease; Myeloma Interventions: Drug: PU-AD; Device: PET Scan; Other: Blood Draws Sponsors: Samus Therapeutics, Inc.; Memorial Sloan Kettering Cancer Center; Weill Medical College of Cornell University; Rockefeller University Recruiting
The first phase 3 trial in patients with newly diagnosed multiple myeloma found that daratumumab significantly improved progression-free survival when combined with triple therapy.Medscape Medical News
This article is protected by copyright. All rights reserved.
In this Key Insights activity, Congress Chair Dr. Morton Coleman and Lymphoma Session Co-Chair Dr. John Leonard discuss highlights of the third day of Lymphoma &Myeloma 2017: An International Congre... Author: imedex Added: 12/13/2017
I had blood tests (and the Bence Jones 24-hour urine test) last week. This afternoon I got my results. Here goes, in a nutshell: My M-spike has gone down (it has actually been going down a wee bit for the past two tests, so this is the third “wee bit down”). Total IgG is also down (for the second time, when compared to my last few tests). My hemoglobin is in the normal range, even though my red blood cells are slightly low, but just slightly. Everything else looks pretty much the same. Almost everything, certainly anything of importance, is a wee bit better compared to my most recent tests. For example, my mon...
Updates from the highly anticipated Phase III MURANO study (NCT02005471) in relapsed/refractory chronic lymphocytic leukemia (CLL) were presented at the American Society of Hematology (ASH) 2017 Annua... Author: VJHemOnc Added: 12/13/2017
In this Key Insights activity, Drs. Morton Coleman and Ruben Niesvizky discuss highlights of the first day of Lymphoma &Myeloma 2017: An International Congress on Hematologic Malignancies held in Oc... Author: imedex Added: 12/13/2017
Cancer research is a fast-advancing field, using the latest technology to better understand the disease. One Albuquerque medical leader is will receive a prestigious honor for using an innovative method to discover what causes certain types of leukemia. Dr. Cheryl Willman, CEO and director of the University of New Mexico's Comprehensive Cancer Center, and Plamen B. Atanassov, director of the UNM Center for Micro-Engineered Materials and a chemical and biological engineering professor, have been…